Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | hydroxysteroid (17-beta) dehydrogenase 4 | Starlite/ChEMBL | No references |
Bacillus subtilis | 4'-phosphopantetheinyl transferase ffp | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 4'-phosphopantetheinyl transferase ffp | 224 aa | 198 aa | 28.3 % |
Trichomonas vaginalis | conserved hypothetical protein | 4'-phosphopantetheinyl transferase ffp | 224 aa | 197 aa | 22.3 % |
Candida albicans | aminoadipate-semialdehyde dehydrogenase small subunit | 4'-phosphopantetheinyl transferase ffp | 224 aa | 183 aa | 27.3 % |
Onchocerca volvulus | 4'-phosphopantetheinyl transferase ffp | 224 aa | 186 aa | 26.3 % | |
Candida albicans | aminoadipate-semialdehyde dehydrogenase small subunit | 4'-phosphopantetheinyl transferase ffp | 224 aa | 183 aa | 27.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | maoC like domain containing protein | 0.0048 | 0.308 | 0.308 |
Entamoeba histolytica | hypothetical protein | 0.0028 | 0.0549 | 0.5 |
Echinococcus multilocularis | L aminoadipate semialdehyde | 0.01 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.308 | 0.308 |
Toxoplasma gondii | sterol carrier protein-2 HAD-2SCP-2 | 0.0043 | 0.2441 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.01 | 1 | 1 |
Mycobacterium leprae | conserved hypothetical protein | 0.0028 | 0.0549 | 0.5 |
Plasmodium falciparum | holo-[acyl-carrier-protein] synthase, putative | 0.0028 | 0.0549 | 0.5 |
Onchocerca volvulus | 0.01 | 1 | 0.5 | |
Plasmodium vivax | holo-[acyl-carrier-protein] synthase, putative | 0.0028 | 0.0549 | 0.5 |
Schistosoma mansoni | aminoadipate-semialdehyde dehydrogenase | 0.01 | 1 | 0.5 |
Mycobacterium ulcerans | dehydratase | 0.0048 | 0.308 | 1 |
Mycobacterium ulcerans | 4'-phosphopantetheinyl transferase | 0.0028 | 0.0549 | 0.1781 |
Chlamydia trachomatis | holo [acyl-carrier protein] synthase | 0.0028 | 0.0549 | 0.5 |
Mycobacterium tuberculosis | holo-[acyl-carrier protein] synthase AcpS (holo-ACP synthase) (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrie | 0.0028 | 0.0549 | 0.1781 |
Mycobacterium ulcerans | hypothetical protein | 0.0048 | 0.308 | 1 |
Treponema pallidum | 4'-phosphopantetheinyl transferase | 0.0028 | 0.0549 | 0.5 |
Leishmania major | phosphopantetheinyl transferase-like protein | 0.0028 | 0.0549 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 4'-phosphopantetheinyl transferase | 0.0028 | 0.0549 | 0.5 |
Toxoplasma gondii | MaoC family domain-containing protein | 0.0029 | 0.063 | 0.0432 |
Mycobacterium tuberculosis | Probable 3-hydroxyacyl-thioester dehydratase HtdY | 0.0048 | 0.308 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0028 | 0.0549 | 0.5 |
Mycobacterium tuberculosis | Probable dehydrogenase. Possible 2-enoyl acyl-CoA hydratase. | 0.0048 | 0.308 | 1 |
Mycobacterium ulcerans | phosphopantetheinyl transferase, PptII | 0.0028 | 0.0549 | 0.1781 |
Echinococcus granulosus | L aminoadipate semialdehyde | 0.01 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.0119 uM | PubChem BioAssay. Gel-Based Assay for Inhibitos of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase): Chemistry Optimization Follow up. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.8061 uM | PubChem BioAssay. Extended Characterization of HPGD Inhibitors: Counterscreen Against HSD17b4. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. Gel-Based Assay for Inhibitos of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase): Chemistry Optimization Follow up. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.